Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.

As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.

Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.

One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are …

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as pre­clin­i­cal and clin­i­cal studies testing new and existing treat­ments for myeloma.

During the session, research …

The Myeloma Beacon has launched its ASH 2013 Multiple Myeloma Gateway.

The new ASH gateway, which will be updated regularly during and after the meeting, is a central launchpad for accessing all the Beacon’s ASH-related content.  That content includes, or will include, Beacon news articles about ASH, abstracts from the meeting, and presentation slides and posters. Readers can easily access the gateway through a link at the top of every page of The Myeloma Beacon.

This is the first …

Earlier this year, I realized that I might need some emotional help.  No matter how determined I am to stay hopeful and positive, living with multiple myeloma and being surrounded by my fellow myeloma patients, some of whom are seriously ill, can take its toll.

Many Americans are reluctant to seek professional help.  Working with a psychologist or psychiatrist is often stigmatized, and mental health is often misunderstood.

Neither of these was a problem for me.  My master’s degree in …

A number of studies to be presented at this year’s American Society of Hema­tol­o­gy (ASH) meeting look at diseases that can progress to mul­ti­ple mye­lo­ma.

These 'myeloma precursor diseases,' as they are sometimes called, in­clude mono­clon­al gammopathy of undetermined significance (MGUS) and smoldering myeloma.

In today's ASH preview article, The Beacon turns its attention to myeloma pre­cursor diseases, reviewing the key studies about them that will be presented at ASH this weekend and early next …

With the holiday season upon us, many of us are thinking about the gifts we plan to give to friends and family members.

For children, the latest toys, pieces of sports equipment, or video games seem to be popular choices. For an adult, it may be a bit more difficult to choose a gift, especially for those who already have everything.

I thought I would share some gift ideas for myeloma patients or their caregivers that may come in …

Results of several studies investigating Revlimid main­te­nance ther­a­py for mul­ti­ple myeloma will be presented at this year’s American Society of Hema­tol­ogy (ASH) annual meeting, which starts later this week.

Today’s article previews the results of the key Revlimid main­te­nance studies that will be presented at the meeting, drawing on findings pub­lished in the meeting abstracts.  Some of the study results, it should be noted, will be updated during the presentations at ASH this week and early next week.

The results …